How to Buy Alkermes Stock
Alkermes PLC
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
Alkermes stock last closed at $55.14, up 1.03% from the previous day, and has increased 88.64% in one year. It has overperformed other stocks in the Drug Manufacturers - Specialty & Generic industry by 1.22 percentage points. Alkermes stock is currently +119.11% from its 52-week low of $25.17, and -0.41% from its 52-week high of $55.37.
There are currently 166.68M shares of ALKS outstanding. The market capitalization of ALKS is $9.19B. In the last 24 hours, 1.72M ALKS shares were traded.
How to Buy Alkermes Stock
Not sure how to invest in Alkermes stock? Here's how.
- Figure out where to buy Alkermes stock: You need to pick a stock brokerage, but don't worry - we've analyzed dozens of online stock brokerages and apps to help you determine where to buy Alkermes stock.
- Open a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Deposit money your investment account: Choose your method of payment and add your info.
- Research Alkermes stock: The Alkermes ticker symbol is ALKS. Is Alkermes stock a good investment? Should you buy shares of ALKS? How do ALKS's underlying business fundamentals look? Do top analysts think Alkermes is a good buy? Why has ALKS's stock price moved recently? (Hint: Our stock market research tools can help you decide if ALKS is a good stock to buy).
- Place your ALKS purchase: Decide if you will purchase ALKS shares at the current market price or use a limit order to purchase ALKS shares at a specific price.
- Get notifications regarding your ALKS investment: Create a watchlist to key updates about your investment in Alkermes stock.
Step 1: Figure out where to buy Alkermes stock
You will need a brokerage account to access the NASDAQ market and buy ALKS stock.
Our recommended brokerage: eToro
Based on our experience, eToro is the best online stock brokerage. Here's why:
- Invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to world financial markets: From Technology to Utilities, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro has a community of more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by creating an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open a brokerage account
Now that you've picked your brokerage, it's time to fill out some personal info so you are able to invest in ALKS stock today.
How to Start a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal data to create your new trading account.
- Submit your details by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit money your investment account
Now that you've created your account on app for investing, you need to deposit funds:
Check out this video walkthrough to see the process of transferring money into your new investment account.
Step 4: Research Alkermes stock
After you have chosen the best place to buy Alkermes stock, it's very important to evaluate their stock before you invest, so you actually wrap your head around the risk and opportunity.
Alkermes stock data
ALKS Due Diligence Checks
WallStreetZen was created to help everyday investors do more in-depth fundamental analysis.
You can view all of the due diligence checks on ALKS's stock page.
What is the fair value of ALKS stock?
Analysts use many financial metrics, analyses, models, and charts to gauge ALKS's true value.
Using relative valuations methods:
- ALKS may be undervalued based on its P/E ratio of 59.29x, relative to Drug Manufacturers - Specialty & Generic industry P/E ratio of -5.96x
- ALKS could be overvalued based on its P/B ratio of 5.25x, relative to Drug Manufacturers - Specialty & Generic industry P/B ratio of 1.59x
- ALKS could be overvalued based on its PEG ratio of 2.8x
You can do more valuation analysis on ALKS's stock here.
ALKS Financials at a glance
Positive Health Checks:
- There are more short-term assets than short-term liabilities on the ALKS balance sheet.
- ALKS earnings of $237.20M is not enough to cover its interest payments.
Negative Health Checks:
- ALKS has a relatively high debt to equity ratio of 1.43.
- ALKS profit margin has gone down from 23.3% to 9.8% in the past year.
- There are more long-term liabilities than short-term assets on the ALKS balance sheet.
- ALKS's operating cash flow of $256.20M allows it to safely service it's debt of $1.58B.
- Total ALKS debt is higher than 5 years ago, relative to shareholder equity.
Do Wall Street analysts think it's a good time to buy Alkermes stock
Out of 10 sell side analysts who monitor ALKS, the consensus analyst rating on ALKS is a Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they financial advice.
Most Recent ALKS Analyst Recommendations
Leonid Timashev, a top 4% analyst from RBC Capital maintains ALKS with a buy rating and raises their ALKS price target from $45.00 to $56.00, on Jun 9, 2026.
Joel Beatty, a top 5% analyst from Baird maintains ALKS with a buy rating and raises their ALKS price target from $45.00 to $48.00, on May 13, 2026.
Ashwani Verma, a top 10% analyst from UBS maintains ALKS with a strong buy rating and raises their ALKS price target from $42.00 to $48.00, on May 6, 2026.
UBS's Ashwani Verma raised their price target on Alkermes (NASDAQ: ALKS) by 14.3% from $42 to $48 on 2026/05/07. The analyst maintained their Strong Buy rating on the stock.
Alkermes reported its Q1 2026 earnings.
Verma backgrounded that increased investor interest in the name was catalyzed by large-cap pharmaceutical corporations' interest in rival orexin programs.
The analyst argued that Alkermes’ initiatives to verify its pipeline and broaden its indication strategy beyond hypersomnolence have the potential to enhance its long-term growth prospects and strategic flexibility.
Earnings Report
For Q1 2026, Alkermes reported:
- Loss per share of $0.40, which beat the Zacks Consensus Estimate of $(0.57) but missed Q1 2025’s $0.13.
- Revenues of $392.91M, which beat the Zacks Consensus Estimate by 9.50% and, by 28.2%, Q1 2025’s $306.51M.
Management did not provide EPS and revenue guidance in its press release.
Chairman & CEO Richard Pops commented: “We delivered a strong quarter marked by solid financial and commercial execution, alongside meaningful strategic progress that positions Alkermes as an emerging leader in sleep medicine.
“During the quarter, we successfully closed the acquisition of Avadel, strengthening our financial profile and accelerating our entry into the commercial sleep medicine market at scale.
“We are also rapidly advancing the alixorexton development program and recently initiated the phase 3 Brilliance studies to further characterize alixorexton’s differentiated profile and potential utility in both narcolepsy type 1 and type 2.
“The multi‑billion‑dollar market opportunity in narcolepsy and idiopathic hypersomnia represents a transformative opportunity for Alkermes.
“Taken together with the broad therapeutic potential across other neuropsychiatric disorders, orexin 2 receptor agonists represent one of the most exciting new therapeutic categories in neuroscience, and Alkermes is at the forefront of generating new clinical data and expanding our understanding of this neurocircuitry.”
David Amsellem, a top 4% analyst from Piper Sandler maintains ALKS with a strong buy rating and lowers their ALKS price target from $45.00 to $43.00, on Mar 24, 2026.
Rudy Li, a top 2% analyst from Wolfe Research initiates coverage on ALKS with a buy rating and announces their ALKS price target of $45.00, on Feb 24, 2026.
You can dig deeper into what analysts are saying on the Alkermes stock forecast page.
ALKS Trading Indicators
Is ALKS Growing Revenue?
Last year, ALKS earnings were $152.72M. Over the past 2 year, ALKS's earnings have increased by -40.42% per year. This was slower than the Drug Manufacturers - Specialty & Generic industry average of 5.2%.
Last year, ALKS revenue was $1.56B. During the last 5 year, ALKS's revenue has increased by 8.4% per year. This was slower than the Drug Manufacturers - Specialty & Generic industry average of 9.41%.
You can research ALKS's earnings and revenue performance here.
Are ALKS insiders buying or selling the stock?
Over the past 12 months, executives and large shareholders at ALKS have sold more shares than they have bought.
David Joseph Gaffin, EVP CLO Alkermes Inc. of ALKS, was the latest ALKS insider to sell. They sold $109,897.02 worth of ALKS stock on Jul 6, 2026.
Research more about who owns ALKS stock here.
Can I rely on ALKS as an income stream?
No, Alkermes doesn't provide an income stream by paying out dividends.
ALKS Social Trading Data
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Place your ALKS purchase
There are two primary options:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are mostly the best for newer investors. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to make sure you're buying or selling at an exact dollar amount, use a limit order.
Press the Open button and your broker will place the order.
If you want more assistance buying stocks on eToro, watch the helpful video below:
Step 6: Get notifications regarding your ALKS investment
Now that you own some ALKS shares, you'll want to stay up-to-date on your new stock purchase.
Add ALKS to a watchlist to get notified of important updates regarding your ALKS stock.
ALKS Feed
How to Buy Stock in Alkermes
To reiterate, here are the 6 steps you need to take to buy Alkermes stock right now:
- Figure out where to buy Alkermes stock
- Open a brokerage account
- Deposit money your investment account
- Research Alkermes stock
- Place your ALKS purchase
- Get notifications regarding your ALKS investment
If you require a online brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to keep tabs on your investment in Alkermes, click below.
Related "How To" Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.